Email This Release
European Commission Approves ADCETRIS® (brentuximab vedotin) with AVD, the First New Treatment in Decades for Adults with Previously Untreated CD30+ Stage IV Hodgkin Lymphoma
*
marks required fields
Recipient Name:
*
Recipient Email:
Message:
*
Enter security words: